BDgene Technology Secures Over RMB 200 Million in Series B Financing Led by Lapam Capital
Gene therapy specialist Shanghai BDgene Technology Co., Ltd has successfully raised over RMB 200 million...
WuXi Biologics Partners with Pharmadule Morimatsu AB for CRDMO Expansion in Singapore
China-based WuXi Biologics (HKG: 2269) has announced a strategic partnership with Sweden-headquartered Pharmadule Morimatsu AB...
CStone Pharmaceuticals’ Gavreto Approved for First-Line RET Fusion-Positive NSCLC Treatment in China
China-based CStone Pharmaceuticals (HKG: 2616) has announced that the National Medical Products Administration (NMPA) of...
CSPC Pharmaceutical’s Biosimilar Omalizumab Accepted for Review by China’s NMPA
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that the National Medical Products Administration...
Henlius Biotech’s HLX13 Biosimilar Gets NMPA Approval for Liver Cancer Clinical Trial
Shanghai Henlius Biotech, Inc (HKG: 2696) has announced receiving clinical trial approval from the National...
Chia Tai Tianqing Launches First Batch of F-627 for Neutropenia Treatment in China
China-based Chia Tai Tianqing has announced the first batch prescriptions in China for its efbemalenograstim...
Jiangsu Kanion Pharmaceutical Gets FDA Approval for KYS202002A Clinical Study in Multiple Myeloma
China-based Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557) has announced receiving the green light from...
Mega Lifesciences Secures Exclusive Rights for Bio-Thera’s Bevacizumab Biosimilar in Indonesia
Thailand-based Mega Lifesciences (BKK: MEGA) has announced an in-licensing agreement with China-based Bio-Thera Solutions (SHA:...
Jiangsu Hengrui’s Dalpiciclib Approved for Initial Therapy in HR+, HER2- Breast Cancer
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...
Fosun Kite’s Yescarta Gains NMPA Approval for Refractory Large B-Cell Lymphoma
China-based Fosun Kite Biotechnology Co., Ltd, a joint venture between Shanghai Fosun Pharmaceutical (Group) Co.,...
Ascletis Pharma’s ASC42 Showcased in Combination Therapy for Chronic Hepatitis B at EASL 2023
China-based Ascletis Pharma Inc. (HKG: 1672) announced the poster presentation of ASC42, a novel farnesoid...
Sinopharm Expands Partnership with Guizhou Government to Boost Health Industry
China National Pharmaceutical Group Corporation (Sinopharm, HKG: 1099) has announced a strengthened partnership with the...
Coherent Biopharma and C-Ray Therapeutics Partner to Advance Peptide-Drug Conjugate Development
China-based Coherent Biopharma and C-Ray Therapeutics have announced a strategic partnership to delve into the...
CANbridge Pharmaceuticals Reports Positive Phase Ib Results for Omoprubart in PNH Treatment
China-based rare disease firm CANbridge Pharmaceuticals Inc., (HKG: 1228) has published the preliminary results of...
Sino Medical Sciences Technology Secures FDA Thailand Approval for NC Rockstar Balloon Catheter
China-based Sino Medical Sciences Technology Inc., (SHA: 688108) has announced that it has received market...
Haisco Pharmaceutical’s HSK31679 Receives Clinical Trial Approval for NASH Treatment
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that its in-house developed Category...
NMPA Approves XZenith Biopharm’s Anaprazole for Duodenal Ulcer Treatment
The National Medical Product Administration (NMPA) has granted marketing approval for anaprazole, a proton pump...
Sichuan Kelun’s SKB264 Earns Breakthrough Therapy Designation for Breast Cancer Treatment
The Center for Drug Evaluation (CDE) website has indicated that China-based Sichuan Kelun Pharmaceutical Co.,...
Brii Biosciences Partners Present Chronic Hepatitis B Clinical Results at EASL 2023
China’s Brii Biosciences (HKG: 2137) announced that its strategic partners, Vir Biotechnology Inc., (NASDAQ: VIR)...
Shionogi’s Acquisition of Qpex Impacts Brii Biosciences’ Rights to Anti-infective Drugs
Japan’s Shionogi & Co., Ltd (TYO: 4507) announced on June 26, 2023, its planned acquisition...